Related Experiment Video
Updated: Apr 20, 2026
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis
R J Commons1, R Grivas, B J Currie
1Department of Infectious Diseases and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
Abstract:
Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80% of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken.
Insights
Melioidosis, a severe sepsis risk, can occur in patients treated with monoclonal antibodies. This first-known case highlights the need for awareness and precautions, especially before travel.
Area of Science:
- Infectious Diseases
- Immunology
- Bacteriology
Background:
- Melioidosis is a severe infectious disease caused by Burkholderia pseudomallei.
- Risk factors for melioidosis are present in 80% of patients.
- Monoclonal antibodies are widely used for various medical conditions.
